Press Releases

July 11, 2023 Lupin Receives EIR from U.S. FDA for its Pithampur Unit-2 Manufacturing Facility

July 4, 2023 Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir Tablets for Oral Suspension

July 3, 2023 Lupin Receives Approval from U.S. FDA for Cyanocobalamin Nasal Spray

June 29, 2023 Lupin Announces Achievement of Key Milestone for its Phase 1 Clinical Stage MALT 1 inhibitor Program

June 23, 2023 Lupin Launches Rufinamide Oral Suspension in the United States

June 21, 2023 Lupin Receives Approval from U.S. FDA for Tiotropium Dry Powder Inhaler

June 20, 2023 Lupin Signs MoU with Government of Maharashtra to Combat Rising Prevalence of Cardiovascular Diseases and COPD

June 19, 2023 Lupin Receives EIR from US FDA for its API Manufacturing Facility in Vizag

June 19, 2023 Lupin Launches Thiamine Hydrochloride Injection USP in the United States